Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According to GlobalData, Phase II drugs for Paranasal Sinus And ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback